KDIGO Clinical Practice Guidelines on Hepatitis C in Chronic Kidney Disease acknowledged by ISN

Abboud, Omar; Becker, Gavin J.; Bellorín-Font, Ezequiel; Field, Michael J.; Johnson, Richard J.; Li, Philip Kt; Wanner, Christoph

doi:10.1038/ncpneph0953

Cited by 13 publications

(13 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This report summarizes recommendations for diagnosis, management, and prevention of kidney disease in this population, including a proposed histologic classification. In the absence of data from randomized controlled trials, these recommendations reflect the expert opinion of conference attendees, incorporating combined clinical experience and evidence from Treatment per existing guidelines 120,155 In patients with HCV genotypes 1 and 4 and CKD G4-5, ribavirin-free grazoprevir/elbasvir [156][157][158] or glecaprevir/pibrentasvir regimens may be effective 164,165 In patients with genotypes 2, 3, 5, and 6 and CKD G4-5, the pan-genotypic glecaprevir/pibrentasvir regimen can be used 164,165 ; sofosbuvir-based regimens can be used in patients with any genotype, but should be avoided or dose adjusted in patients with eGFR < 30 ml/min per 1.73 m 2 . [159][160][161] In addition, the combination of ledipasvir and sofosbuvir with TDF should be avoided.…”

Section: Resultsmentioning

confidence: 99%

Kidney Disease in the Setting of Hiv Infection: Conclusions From a Kidney Disease: Improving Global Outcomes (Kdigo) Controversies Conference

Сванепоэль

Atta

D’Agati

et al. 2018

Nefrologiâ (St.-Peterbg.)

View full text Add to dashboard Cite

HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge o f the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.

show abstract

Section: Resultsmentioning

confidence: 99%

Kidney Disease in the Setting of Hiv Infection: Conclusions From a Kidney Disease: Improving Global Outcomes (Kdigo) Controversies Conference

Сванепоэль

Atta

D’Agati

et al. 2018

Nefrologiâ (St.-Peterbg.)

View full text Add to dashboard Cite

show abstract

“…Despite a presumed indolent course, HCV antibody positive dialysis patients have an increased risk for allcause mortality compared with uninfected patients. 13 A meta-analysis of 14 observational studies including 145,608 dialysis patients, demonstrated an association between HCV infection and increased mortality, with an adjusted relative risk (ARR) of 1.32 (95% CI 1.24-1.42). The ARR of liver related death in HCV-positive patients was 3.82 (95% CI 1.92-7.61), and was primarily a result of chronic liver disease, complications of cirrhosis and hepatocellular carcinoma.…”

Section: Hcv Infection Increases All-cause Morbidity and Mortality Inmentioning

confidence: 99%

“…Despite a presumed indolent course, HCV antibody positive dialysis patients have an increased risk for all‐cause mortality compared with uninfected patients . A meta‐analysis of 14 observational studies including 145,608 dialysis patients, demonstrated an association between HCV infection and increased mortality, with an adjusted relative risk (ARR) of 1.32 (95% CI 1.24–1.42).…”

Section: Introductionmentioning

confidence: 99%

Rationale for treatment of hepatitis C virus infection in end‐stage renal disease patients who are not kidney transplant candidates

Al‐Rabadi

Box

Singhania

et al. 2018

Hemodialysis International

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a common problem in patients treated with maintenance hemodialysis (HD) and is associated with an increased morbidity and mortality and lower quality of life. The major causes of HCV-associated mortality are liver and cardiovascular-related death. HCV-infected HD patients have a higher prevalence of inflammation-related metabolic and vascular diseases, leading to high rates of cardiovascular mortality in patients with end-stage renal disease. In the current era of highly effective direct-acting antiviral regimens, HCV treatment may also confer hepatic, cardiovascular and other morbidity and mortality benefits even to dialysis-dependent patients who do not qualify for kidney transplantation. Currently, the most accepted regimens in this patient population include elbasvir/grazoprevir and glecaprevir/pibrentasvir.

show abstract

“…Hypovitaminosis D, defined by serum levels of 25OHD less than 30 ng/Ml (12), is common among patients referred for kidney transplantation. It occurs mainly during the first months after transplantation and may be related to limited sunlight exposure and sun blockers use, hepatic dysfunction and use of GCs, which may increases catabolism of 25-OHD (13).…”

Section: -Hidroxyvitamin D (25ohd)mentioning

confidence: 99%

Bone disease after transplantation: osteoporosis and fractures risk

Kulak

Borba

Kulak

et al. 2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Organ transplantation is the gold standard therapy for several end-stage diseases. Bone loss is a common complication that occurs in transplant recipients. Osteoporosis and fragility fractures are serious complication, mainly in the first year post transplantation. Many factors contribute to the pathogenesis of bone disease following organ transplantation. This review address the mechanisms of bone loss including the contribution of the immunosuppressive agents as well as the specific features to bone loss after kidney, lung, liver, cardiac and bone marrow transplantation. Prevention and management of bone loss in the transplant recipient should be included in their post transplant follow-up in order to prevent fractures. Arq Bras Endocrinol Metab. 2014;58(5):484-92Keywords Transplantation; bone loss; osteoporosis; fractures; immunosuppressive agents RESUMOTransplantes de órgão é terapia padrão-ouro para várias doenças em estágio terminal. Perda óssea é uma complicação comum que ocorre em pacientes transplantados. Osteoporose e fraturas por fragilidade são complicações sérias, principalmente no primeiro ano pós-transplante. Muitos fatores podem contribuir para patogênese da doença óssea nesses pacientes. Esta revisão aborda os mecanismos de perda óssea incluindo o papel dos agentes imunossupressores, bem como os fatores específicos da perda óssea após rim, pulmão, fígado, coração e transplante de medula óssea. A prevenção e o tratamento da perda óssea nos pacientes transplantados devem ser realizados para evitar fraturas. Arq Bras Endocrinol Metab. 2014;58(5):484-92 Descritores

show abstract

KDIGO Clinical Practice Guidelines on Hepatitis C in Chronic Kidney Disease acknowledged by ISN

Cited by 13 publications

References 2 publications

Kidney Disease in the Setting of Hiv Infection: Conclusions From a Kidney Disease: Improving Global Outcomes (Kdigo) Controversies Conference

Kidney Disease in the Setting of Hiv Infection: Conclusions From a Kidney Disease: Improving Global Outcomes (Kdigo) Controversies Conference

Rationale for treatment of hepatitis C virus infection in end‐stage renal disease patients who are not kidney transplant candidates

Bone disease after transplantation: osteoporosis and fractures risk

Contact Info

Product

Resources

About